News

Biotechnology

​Lexaria Bioscience Arranges Private Placement Financing to Fund New Laboratory

​Lexaria Bioscience Arranges Private Placement Financing to Fund New Laboratory

Spotlight News | Equities.com |

Lexaria Bioscience Corp. LXRP LXX:CNX, a drug delivery platform innovator, announces it has arranged a non-brokered private placement for gross proceeds of approximately US$1 million.


resTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections

Equities Research | Equities.com |

RTB101 shown to decrease incidence of infection with severe symptoms by 52.1% vs placebo (Image: resTORbio)


AcelRx Gets FDA Advisory Committee Recommendation for Acute Pain Therapy

Equities Research | Equities.com |

Anesthetic & Analgesic Drug Products Advisory Committee voted 10-3 in recommending approval of Dsuvia (sublingual sufentanil) for acute pain in medically supervised settings (Image: AcelRx).


PhaseBio's $65 Million IPO Expected Next Week for Orphan Cardiopulmonary Diseases

Equities Research | Equities.com |

Clinical candidates for reversal agent for antiplatelet drug and for pulmonary arterial hypertension (Image: PhaseBio Pharmaceuticals)


TG Therapeutics Shows Positive Final Phase 2 Data in Relapsing Multiple Sclerosis

Equities Research | Equities.com |

Data presented at ECTRIMS, the world's largest MS conference (Image: TG Therapeutics)


Gotham Therapeutics Launches with $54 Million Co-Led by Versant Ventures, Forbion and SR One

Equities Research | Equities.com |

Pioneering RNA modification to control gene expression (Image: Gotham Therapeutics)


​Lexaria Bioscience Creates and Brands Subsidiary Companies

Spotlight News | Equities.com |

Lexaria Bioscience Corp. LXRP LXX:CNX, a drug delivery platform innovator, is pleased to announce it has completed the creation of four wholly-owned subsidiary companies.


Equillium's $70 Million IPO Expected This Week for Immuno-Inflammatory Diseases

Equities Research | Equities.com |

Lead candidate targeting graft-versus-host disease (GvHD) (Image: Equillium).


Novartis to Get Expedited FDA Review of Secondary Progressive Multiple Sclerosis Drug

Equities Research | Equities.com |

Phase 3 data shows siponimod has beneficial effects on disability, relapses and MRI disease activities (Image: Novartis)


​The Company Partnering with Canada's Research Council on Cannabinoid Biosynthesis

Stephen L Kanaval | Equities.com |

Inmed Pharmaceuticals Inc. is using cannabinoids to fight hard to treat diseases.


Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Events

BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to…

Learn more